Free Trial

Nuwellis Q2 2023 Earnings Report

Nuwellis logo
$1.00 -0.01 (-0.99%)
(As of 12/20/2024 05:31 PM ET)

Nuwellis Earnings Headlines

Nuwellis regains Nasdaq compliance with bid and equity rules
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Nuwellis Regains Compliance with Nasdaq Listing Requirements
Nuwellis files to sell 3.73M shares of common stock for holders
See More Nuwellis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuwellis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuwellis and other key companies, straight to your email.

About Nuwellis

Nuwellis (NASDAQ:NUWE), a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

View Nuwellis Profile

More Earnings Resources from MarketBeat

Upcoming Earnings